Therapeutic Attributes of Panchasama Churna in Pain Management: A Comprehensive Review

Panchasama churna is a classical polyherbal Ayurvedic formulation described by Acharya Chakradutta, Yogaratnakara, and Sharangadhara in the context of Amavata chikitsa.Traditionally indicated for conditions such as Agnimandya, Ajeerna, and Anaha, it comprises equal proportions of Trivrut (Operculina turpethum), Shunthi (Zingiber officinale), Pippali (Piper longum), Haritaki (Terminalia chebula Retz), and Souvarchala lavana.The formulation is designed to correct impaired digestion and eliminate Ama, the central pathological factor in Amavata.Relevant literature was retrieved from PubMed, Scopus, DHARA, Google Scholar, and ScienceDirect using predefined search terms related to Panchasama churna and its constituent drugs.The available evidence was critically reviewed to assess their therapeutic relevance in pain and Amavata.A critical appraisal of the individual components of Panchasama churna underscores their therapeutic relevance in rheumatoid arthritis, with contemporary pharmacological evidence indicating that key ingredients such as Shunthi, Haritaki, Pippali, and Trivrut exhibit significant analgesic, anti-inflammatory, and immunomodulatory properties.Several of these herbs have been shown to modulate critical inflammatory mediators and signalling pathways-including cyclooxygenase (COX), 5-lipoxygenase (5-LOX), tumor necrosis factor-alpha (TNF-α), and nuclear factor kappa B (NF-κB)-which are central to the pathogenesis of rheumatoid arthritis.The convergence of classical Ayurvedic principles with modern pharmacological insights provides a strong rationale for the use of Panchasama churna in the treatment of Amavata.While the formulation demonstrates considerable potential as a safe and effective complementary therapeutic approach, further experimental studies and rigorously designed clinical trials are essential to establish standardised treatment protocols and validate its clinical efficacy.However, the available evidence is predominantly preclinical, and the lack of high-quality clinical trials limits definitive conclusions regarding its clinical efficacy.